What Happens to Estrogen Levels When You Start TRT?
What Happens to Estrogen Levels When You Start TRT? June 14, 2026 10 min read Testosterone Replacement Therapy Table of
June 21, 2026
No Comments
If you have been researching testosterone replacement therapy, you have probably come across concerns about heart health. For years, the relationship between testosterone and cardiovascular risk was a source of significant debate in the medical community, driven largely by early studies that raised alarms without providing complete answers.
The research has evolved considerably since then. What the current evidence shows is more nuanced than either the early warnings or the enthusiastic dismissals of those warnings suggested. Understanding what the science actually says about testosterone and heart health is an important step for any man considering TRT.
This guide covers the history of the controversy, what current evidence shows, the specific cardiovascular factors that TRT affects, and how proper medical oversight addresses those concerns in practice.
Testosterone influences a wide range of physiological systems, and the cardiovascular system is among them. Testosterone affects red blood cell production, lipid metabolism, body composition, blood pressure regulation, and vascular function. Each of these pathways has implications for heart health, which is why the relationship between the two has attracted significant research attention.
Low testosterone itself is associated with several cardiovascular risk factors. Men with clinically low testosterone levels tend to have higher rates of obesity, metabolic syndrome, insulin resistance, and type 2 diabetes, all of which increase cardiovascular risk independent of testosterone levels. This creates a complex picture where low testosterone and poor cardiovascular health are associated without one necessarily causing the other.
The question that has occupied researchers for over a decade is whether testosterone replacement therapy improves, worsens, or has a neutral effect on cardiovascular outcomes in men with testosterone deficiency.
The cardiovascular controversy around TRT began in earnest in 2010 with a study published in the New England Journal of Medicine that was stopped early due to a higher rate of cardiovascular events in the testosterone group. That study involved older men with mobility limitations and a high prevalence of pre-existing cardiovascular disease, making its findings difficult to generalize to healthier men with testosterone deficiency.
A 2013 observational study raised similar concerns, finding associations between TRT use and cardiovascular events in a VA patient database. However, subsequent analyses found significant methodological problems with that study, including errors in how patient data was classified.
These early studies created a climate of concern that was not fully supported by the totality of evidence available even at the time. The limitations of observational studies, where correlation and causation are frequently confused, made it difficult to draw reliable conclusions.
The most significant development in understanding testosterone and heart health came with the TRAVERSE trial, a large randomized controlled trial specifically designed to evaluate the cardiovascular safety of testosterone therapy in middle-aged and older men with low testosterone and elevated cardiovascular risk.
The TRAVERSE trial results, published in the New England Journal of Medicine in 2023, found that testosterone therapy was non-inferior to placebo for major cardiovascular events including heart attack and stroke. This was a meaningful finding because it came from a rigorously designed trial that directly addressed the cardiovascular safety question rather than inferring it from observational data.
The trial also found a higher rate of atrial fibrillation in the testosterone group, which is a finding worth noting and discussing with your provider, particularly if you have a history of heart rhythm issues.
According to guidelines from the American Urological Association, TRT is not contraindicated in men with controlled cardiovascular disease, though it requires appropriate evaluation and monitoring. The current clinical consensus is that properly managed TRT in appropriately selected patients does not significantly increase cardiovascular risk and may offer metabolic benefits that support cardiovascular health indirectly.
Understanding specifically how TRT affects cardiovascular-related markers helps men and their providers make more informed decisions about treatment and monitoring.
Testosterone stimulates red blood cell production, which raises hematocrit, the proportion of blood volume made up of red blood cells. Elevated hematocrit thickens the blood, which can increase the risk of clotting events including deep vein thrombosis, pulmonary embolism, and stroke if not monitored and managed.
This is one of the most important reasons why hematocrit monitoring is a non-negotiable component of responsible TRT management. Most providers set a threshold around 54 percent hematocrit, above which dose reduction or temporary treatment pause is indicated.
The effect of TRT on cholesterol levels varies depending on the delivery method and the individual patient. Injectable testosterone has been shown in some studies to modestly reduce HDL cholesterol, which is the protective form of cholesterol. Topical formulations tend to have less pronounced effects on lipid profiles.
Regular lipid monitoring during TRT allows providers to identify and respond to any clinically significant changes before they become long-term concerns.
Some men experience modest increases in blood pressure on TRT, particularly if hematocrit rises. Regular blood pressure monitoring is a standard part of TRT follow-up care and allows for early identification and management of this risk.
One of the more cardioprotective effects of TRT is its impact on body composition. Testosterone supports muscle mass and reduces abdominal fat, both of which are associated with improved metabolic and cardiovascular health. For men who were obese or had metabolic syndrome before starting TRT, these body composition changes can produce meaningful indirect cardiovascular benefits.
As noted in the TRAVERSE trial, testosterone therapy was associated with a modestly higher rate of atrial fibrillation. Men with a personal or family history of atrial fibrillation should discuss this finding specifically with their provider before starting TRT.
While current evidence supports the cardiovascular safety of TRT in appropriately selected patients, certain men require extra evaluation and caution before beginning treatment.
Men with a recent history of heart attack or stroke, men with severe or uncontrolled heart failure, men with a history of atrial fibrillation, and men with significantly elevated hematocrit at baseline all warrant careful individual evaluation before TRT is initiated.
This does not mean TRT is automatically ruled out for these men. It means the risk-benefit conversation needs to be thorough, individualized, and ideally conducted in coordination with any cardiologist or specialist involved in their care.
A qualified provider will gather a complete cardiovascular history, review all current medications, and assess baseline lab values including hematocrit, lipids, and PSA before making any treatment recommendation.
The cardiovascular risks associated with TRT are not hidden or untreatable. They are manageable through consistent, protocol-driven monitoring. This is one of the most important reasons why TRT should always be managed by a qualified provider rather than pursued through unmonitored channels.
Standard monitoring during testosterone replacement therapy includes hematocrit and CBC at regular intervals, lipid panel monitoring, blood pressure tracking, PSA monitoring, and testosterone level checks to ensure dosing stays within the therapeutic range.
For men who prefer to manage their care without in-person clinic visits, out-of-state telehealth consultations provide full access to this monitoring through local lab draws and virtual provider reviews. The standard of care is the same regardless of whether the consultation happens in person or virtually.
Men who are in the early stages of evaluating whether TRT may be appropriate for their symptoms can begin with the ADAM Questionnaire for Men, a validated symptom screening tool that helps identify whether low testosterone may be contributing to the symptoms they are experiencing.
Current evidence from the TRAVERSE trial, the largest randomized controlled trial specifically designed to evaluate TRT cardiovascular safety, found that testosterone therapy was not associated with a higher rate of heart attacks or strokes compared to placebo. Earlier observational studies raised concerns that have not been confirmed by higher-quality evidence.
Yes. Low testosterone is associated with higher rates of metabolic syndrome, obesity, insulin resistance, and type 2 diabetes, all of which are independent cardiovascular risk factors. Some research suggests that addressing testosterone deficiency may indirectly support cardiovascular health by improving body composition and metabolic function.
Men with a recent history of heart attack require individual evaluation before starting TRT. Most guidelines recommend waiting at least three to six months after a cardiac event before considering TRT, and the decision should involve coordination between the prescribing provider and the patient’s cardiologist.
Delivery method can influence certain cardiovascular markers differently. Injectable testosterone tends to produce larger fluctuations in testosterone levels and may have a more pronounced effect on hematocrit and lipids compared to topical formulations. Your provider can explain how different delivery methods compare given your specific cardiovascular history.
Most providers check hematocrit and lipids at baseline, at three months after starting treatment, and then every six months once levels are stable. Blood pressure should be monitored at every provider contact. If any values rise above safe thresholds, the monitoring frequency increases accordingly.
Men on anticoagulant therapy require careful evaluation before starting TRT because of the interaction between elevated hematocrit and clotting risk. This is a conversation that must involve your prescribing provider and, in many cases, the provider managing your anticoagulation.
If you have questions about testosterone and heart health and want to understand whether TRT is appropriate for your specific situation, speaking with a qualified provider is the most important next step. A thorough evaluation will review your cardiovascular history, baseline lab values, and symptoms to determine whether treatment is appropriate and what monitoring plan makes sense for you.
The relationship between testosterone and heart health is real but more reassuring than early research suggested. The TRAVERSE trial provided the strongest evidence to date that properly managed TRT does not significantly increase the risk of major cardiovascular events in men with low testosterone. The most important cardiovascular considerations during TRT are hematocrit elevation, lipid changes, and the modest association with atrial fibrillation observed in recent trials. All of these are manageable through consistent monitoring with a qualified provider. Men with pre-existing cardiovascular conditions are not automatically excluded from TRT but do require more thorough individual evaluation and ongoing oversight. The indirect cardiovascular benefits of TRT, including improved body composition, reduced abdominal fat, and better metabolic function, may offer meaningful long-term support for heart health in men with testosterone deficiency.
Learn more about testosterone replacement therapy and what a responsible treatment program looks like from initial evaluation through ongoing care. If you are located outside of Maryland, out-of-state consultation options are available for residents of multiple states.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. The content is not intended to diagnose, treat, cure, or prevent any medical condition. Always consult a qualified healthcare provider before starting, stopping, or modifying any medication or treatment plan. Individual results and risks vary based on personal health history and clinical factors.
What Happens to Estrogen Levels When You Start TRT? June 14, 2026 10 min read Testosterone Replacement Therapy Table of
What Is Insulin Resistance and Why Does It Make Weight Loss So Hard? June 21, 2026 10 min read Medical
Why Am I Not Losing Weight on Semaglutide? What to Do When Results Stall June 28, 2026 10 min read
What Is Food Noise and How Do GLP-1 Medications Help Quiet It? May 24, 2026 10 min read Medical Weight
Currently only accepting new clients from: New Mexico, Utah, Minnesota, Maryland, Virginia, Delaware, Colorado, West Virginia, Arizona, Iowa, Florida, Nevada, and Connecticut.